Lake-Breaking SMA Treatment Insights You May Have Missed in February
February wrapped up with a surge of data on SMA, including novel investigations into how combinatorial therapies may provide new advantages to those with the disease. More information on how nusinersen impacts patients has also become available, as have new findings...
Spinal Muscular Atrophy: Late-July Monthly Roundup
In July, the literature pertaining to spinal muscular atrophy (SMA) has focused mainly on understanding the disease. Information on treatments has been published largely in review form, while there has also been some new information on managing the disease and what...
Spinal Muscular Atrophy: June Bi-Monthly Roundup
Since our last roundup, there has been continued focus in the spinal muscular atrophy (SMA) literature how best to treat the disease. There also continues to be research geared toward understanding the biology of the disease, as well as on SMA management, what it is...
Spinal Muscular Atrophy: Monthly Roundup
Much of the most recent research regarding spinal muscular atrophy (SMA) has focused on understanding the mechanisms mediating the disease as well as the clinical value of different pharmaceutical interventions. There have been several reviews on the latter topic,...
FDA Approves AveXis’ Gene Therapy Zolgensma to Treat SMA in Children Up to Age 2
Zolgensma, a first gene therapy for spinal muscular atrophy — and first for any chronic neurologic disease — is now an approved and potential “one-time” intravenous treatment for pre-symptomatic newborns through 2-year-olds with any type of SMA, the U.S. Food and Drug...HCP — SMA News Today
BioNews Services, LLC
1601 Market St.
Suite 20B103
Philadelphia, PA 19103
Email: [email protected]
Phone: 1-800-936-1363